<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="59520"><DrugName>human embryonic stem cell-derived motor neuron progenitors (neuromuscular disease), NeoStem Oncology/Cellular Biomedicine</DrugName><DrugSynonyms><Name><Value>human embryonic stem cell-derived motor neuron progenitors (neuromuscular disease), Neostem Oncology</Value></Name><Name><Value>hESC-derived MNPs (neuromuscular disease), CSC</Value></Name><Name><Value>MotorGraft</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>human embryonic stem cell-derived motor neuron progenitors (neuromuscular disease), NeoStem Oncology/Cellular Biomedicine</Value></Name><Name><Value>human embryonic stem cell-derived motor neuron progenitors (neuromuscular disease), California Stem Cell/Cellular Biomedicine</Value></Name><Name><Value>human embryonic stem cell-derived motor neuron progenitors (neuromuscular disease), California Stem Cell</Value></Name></DrugSynonyms><CompanyOriginator id="1037722">Neostem Oncology</CompanyOriginator><CompaniesPrimary><Company id="1080369">Cellular Biomedicine Group Inc</Company><Company id="1037722">Neostem Oncology</Company></CompaniesPrimary><CrossReferences><SourceEntity id="59520" type="Drug"><TargetEntity id="676207" type="siDrug">hESC-MNP</TargetEntity></SourceEntity><SourceEntity id="1037722" type="Company"><TargetEntity id="4297747799" type="organizationId">California Stem Cell Inc</TargetEntity></SourceEntity><SourceEntity id="1080369" type="Company"><TargetEntity id="5038909966" type="organizationId">Cellular Biomedicine Group HK Ltd</TargetEntity></SourceEntity><SourceEntity id="212" type="ciIndication"><TargetEntity id="G12.2" type="ICD10"/><TargetEntity id="10028003" type="MEDDRA"/><TargetEntity id="D016472" type="MeSH"/><TargetEntity id="1290" type="siCondition"/></SourceEntity><SourceEntity id="234" type="ciIndication"><TargetEntity id="10029317" type="MEDDRA"/><TargetEntity id="D009468" type="MeSH"/><TargetEntity id="-451142170" type="omicsDisease"/><TargetEntity id="155" type="siCondition"/></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"/><TargetEntity id="-1815339002" type="omicsDisease"/><TargetEntity id="93" type="siCondition"/></SourceEntity><SourceEntity id="727" type="ciIndication"><TargetEntity id="G12" type="ICD10"/><TargetEntity id="10041582" type="MEDDRA"/><TargetEntity id="D009134" type="MeSH"/><TargetEntity id="-1479956298" type="omicsDisease"/><TargetEntity id="1242" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="4">Advanced Therapy Medicinal Product</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="212">Motor neurone disease</Indication><Indication id="234">Neuromuscular disease</Indication><Indication id="65">Stroke</Indication><Indication id="727">Spinal muscular atrophy</Indication></IndicationsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="886">Neurogenic potential stem cell therapy</Technology><Technology id="858">Embryonic stem cell therapy</Technology><Technology id="857">Allogenic stem cell therapy</Technology></Technologies><LastModificationDate>2019-05-30T07:15:32.000Z</LastModificationDate><ChangeDateLast>2018-04-20T00:00:00.000Z</ChangeDateLast><AddedDate>2008-02-20T09:48:47.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1037722" linkType="Company"&gt;NeoStem Oncology&lt;/ulink&gt; (formerly  California Stem Cell (CSC), until the acquisition of CSC by &lt;ulink linkID="1010647" linkType="Company"&gt;Caladrius Biosciences&lt;/ulink&gt;),  in collaboration with Chinese licensee, &lt;ulink linkID="1080369" linkType="Company"&gt;Cellular Biomedicine Group&lt;/ulink&gt;,  is investigating  MotorGraft, allogeneic human embryonic stem cell (hESC)-derived motor neuron progenitors (MNPs), for the potential treatment of neuromuscular conditions such as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and stroke [&lt;ulink linkID="877768" linkType="Reference"&gt;877768&lt;/ulink&gt;], [&lt;ulink linkID="878079" linkType="Reference"&gt;878079&lt;/ulink&gt;], [&lt;ulink linkID="1350107" linkType="Reference"&gt;1350107&lt;/ulink&gt;], [&lt;ulink linkID="1548062" linkType="Reference"&gt;1548062&lt;/ulink&gt;], [&lt;ulink linkID="1548063" linkType="Reference"&gt;1548063&lt;/ulink&gt;], [&lt;ulink linkID="1548072" linkType="Reference"&gt;1548072&lt;/ulink&gt;], [&lt;ulink linkID="1554915" linkType="Reference"&gt;1554915&lt;/ulink&gt;], [&lt;ulink linkID="1554947" linkType="Reference"&gt;1554947&lt;/ulink&gt;], [&lt;ulink linkID="1664765" linkType="Reference"&gt;1664765&lt;/ulink&gt;]. In December 2010, CSC filed an IND application for a phase I study for SMA type I [&lt;ulink linkID="1243816" linkType="Reference"&gt;1243816&lt;/ulink&gt;]; in February 2011, the FDA placed the proposed study on clinical hold, recommending that further preclinical work be completed  [&lt;ulink linkID="1244207" linkType="Reference"&gt;1244207&lt;/ulink&gt;].  In June 2013, an active IND for a phase I SMA trial was on file with the FDA, and an IND filing for an ALS trial was in preparation in the US; at that time, the company was also planning to start phase I/IIa studies in the UK [&lt;ulink linkID="1444123" linkType="Reference"&gt;1444123&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2009, the  FDA granted MotorGraft Orphan Drug status for the treatment of SMA [&lt;ulink linkID="1063066" linkType="Reference"&gt;1063066&lt;/ulink&gt;]. In January 2014, the FDA granted the product Orphan designation for the treatment of ALS [&lt;ulink linkID="1518656" linkType="Reference"&gt;1518656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By June 2013, MotorGraft had been granted the Advanced Therapy Medicinal Product (ATMP) classification by the UK MHRA [&lt;ulink linkID="1444123" linkType="Reference"&gt;1444123&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, the EMA's COMP recommended granting the product Orphan status for the treatment of 5q SMA [&lt;ulink linkID="1350107" linkType="Reference"&gt;1350107&lt;/ulink&gt;]; Orphan status was granted in January 2013 [&lt;ulink linkID="1383024" linkType="Reference"&gt;1383024&lt;/ulink&gt;]. In June 2013, the COMP recommended granting the product Orphan status for the treatment of ALS [&lt;ulink linkID="1442730" linkType="Reference"&gt;1442730&lt;/ulink&gt;]; in July 2013, Orphan status was granted [&lt;ulink linkID="1472374" linkType="Reference"&gt;1472374&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2009, phase I studies in  type 1 infantile SMA were expected that year [&lt;ulink linkID="988646" linkType="Reference"&gt;988646&lt;/ulink&gt;]. In October 2009, a pre-IND meeting was held with the FDA [&lt;ulink linkID="1049561" linkType="Reference"&gt;1049561&lt;/ulink&gt;]. In December 2009, an IND filing was planned and a phase I safety trial was expected to begin in 2010 [&lt;ulink linkID="1063066" linkType="Reference"&gt;1063066&lt;/ulink&gt;].  In February 2010, the FDA were still reviewing safety data prior to approving the trial [&lt;ulink linkID="1172743" linkType="Reference"&gt;1172743&lt;/ulink&gt;]. In December 2010, CSC filed an IND application for a phase I study for SMA type I [&lt;ulink linkID="1243816" linkType="Reference"&gt;1243816&lt;/ulink&gt;]. In February 2011, the FDA placed the proposed study on clinical hold, recommending that CSC conduct a preclinical safety study in an additional species and complete ongoing SMA animal studies [&lt;ulink linkID="1244207" linkType="Reference"&gt;1244207&lt;/ulink&gt;]. In November 2011, it was reported at the Fourth BIT Regenerative Medicine and Stem Cell Meeting in Beijing, China, that the clinical study was to be carried out in one site and enroll 8 infants 2 to 6 months old in 2 cohorts of 4. The primary endpoint would be safety, with a secondary endpoint of improved respiration and quality of life [&lt;ulink linkID="1242884" linkType="Reference"&gt;1242884&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By February 2010, CSC and &lt;ulink linkID="30843" linkType="Company"&gt;ALS Therapy Development Institute&lt;/ulink&gt; (ALS TDI)  conducted experiments to transplant stem cell progenitor motor neurons into the spinal cords of SOD1 mice, which had been engineered to  mimic ALS. Â Results demonstrated that the transplanted cells survive, integrate, and display motor neuron markers. In February 2010, ALS TDI would confirm expression of certain genes in vivo by using its Knowledgesphere gene and protein expression database, and MotorGraft to deliver gene expression modifying payloads to specific CNS locations. Efficacy experiments with CSC would then be conducted to measure any potential ameliorating disease [&lt;ulink linkID="1072477" linkType="Reference"&gt;1072477&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2009, preclinical GLP safety and efficacy studies had been completed [&lt;ulink linkID="1065294" linkType="Reference"&gt;1065294&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2008, CSC's high purity MNP populations had been used successfully in proof of concept efficacy and preliminary safety studies at the &lt;ulink linkID="26270" linkType="Company"&gt;University of California, Irvine&lt;/ulink&gt; [&lt;ulink linkID="877768" linkType="Reference"&gt;877768&lt;/ulink&gt;]. In December 2009,  preclinical data     were reported demonstrating the therapy to be safe and to provide functional benefit in several animal models [&lt;ulink linkID="1063066" linkType="Reference"&gt;1063066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, preclinical data, demonstrating the  use of mouse ESC-derived motor neurons in rats, were published [&lt;ulink linkID="877768" linkType="Reference"&gt;877768&lt;/ulink&gt;], [&lt;ulink linkID="878136" linkType="Reference"&gt;878136&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2008, CSC and the &lt;ulink linkID="1037731" linkType="Company"&gt;Families of Spinal Muscular Atrophy&lt;/ulink&gt; (FSMA) established a partnership to advance the product into clinical trials. Under the terms of the alliance, FSMA facilitated the transfer of a $0.2 million donation to CSC for further  animal studies [&lt;ulink linkID="877768" linkType="Reference"&gt;877768&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1037722">Neostem Oncology</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2013-06-11T00:00:00.000Z</StatusDate><Source id="1442730" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1080369">Cellular Biomedicine Group Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="727">Spinal muscular atrophy</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate><Source id="1548072" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037722">Neostem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="234">Neuromuscular disease</Indication><StatusDate>2008-02-19T00:00:00.000Z</StatusDate><Source id="877768" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037722">Neostem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate><Source id="1548072" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037722">Neostem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2008-02-19T00:00:00.000Z</StatusDate><Source id="877768" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1080369">Cellular Biomedicine Group Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate><Source id="1548072" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037722">Neostem Oncology</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="727">Spinal muscular atrophy</Indication><StatusDate>2012-12-05T00:00:00.000Z</StatusDate><Source id="1350107" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1080369">Cellular Biomedicine Group Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="234">Neuromuscular disease</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate><Source id="1548072" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1080369">Cellular Biomedicine Group Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="212">Motor neurone disease</Indication><StatusDate>2013-06-18T00:00:00.000Z</StatusDate><Source id="1548072" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037722">Neostem Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="727">Spinal muscular atrophy</Indication><StatusDate>2008-02-19T00:00:00.000Z</StatusDate><Source id="877768" type="PR"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="4">Advanced Therapy Medicinal Product</RegulatoryDesignation><OwnerCompany id="1037722">Neostem Oncology</OwnerCompany><Country id="EU">EU</Country><Indication id="234">Neuromuscular disease</Indication><AwardedIndication>Neuromuscular disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-06-25T00:00:00.000Z</MileStoneDate><Source id="1444123" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037722">Neostem Oncology</OwnerCompany><Country id="US">US</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of Amyotrophic Lateral Sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-01-17T00:00:00.000Z</MileStoneDate><Source id="1518656" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037722">Neostem Oncology</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-07-17T00:00:00.000Z</MileStoneDate><Source id="1472374" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037722">Neostem Oncology</OwnerCompany><Country id="EU">EU</Country><Indication id="212">Motor neurone disease</Indication><AwardedIndication>Treatment of amyotrophic lateral sclerosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2013-06-13T00:00:00.000Z</MileStoneDate><Source id="1442730" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037722">Neostem Oncology</OwnerCompany><Country id="EU">EU</Country><Indication id="727">Spinal muscular atrophy</Indication><AwardedIndication>Treatment of 5q spinal muscular atrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-01-24T00:00:00.000Z</MileStoneDate><Source id="1383024" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037722">Neostem Oncology</OwnerCompany><Country id="EU">EU</Country><Indication id="727">Spinal muscular atrophy</Indication><AwardedIndication>Treatment of 5q spinal muscular atrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2012-02-06T00:00:00.000Z</MileStoneDate><Source id="1350107" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037722">Neostem Oncology</OwnerCompany><Country id="US">US</Country><Indication id="727">Spinal muscular atrophy</Indication><AwardedIndication>Treatment of spinal muscular atrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-11-25T00:00:00.000Z</MileStoneDate><Source id="1063066" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1010647">Caladrius Biosciences Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1037731">Families of Spinal Muscular Atrophy</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1080369">Cellular Biomedicine Group Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30843">ALS Therapy Development Institute</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="1">Drug - Discovery/Design</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="111686" title="FSMA to fund CSC's preclinical stem cell therapy studies "/><Deal id="114306" title="CSC and ALS TDI to collaborate on stem cell treatment of ALS  "/><Deal id="145575" title="CBMG to develop and commercialize CSC's TC-DC therapy for hepatocellular carcinoma in China and Taiwan     "/></Deals><PatentFamilies><PatentFamily id="1484317" number="US-08465975" title="Human late stage motor neuron progenitor cells produced from pluripotent stem cells"/><PatentFamily id="200283" number="WO-2008118421" title="Human late stage motor neuron progenitor cells and methods of making and using same"/><PatentFamily id="3408573" number="WO-2016164915" title="Stem cell compositions for cosmetic and dermatologic use"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Caladrius Biosciences Inc" id="1010647"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ALPHAEON Corp" id="1108433"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>